LevelJump Announces 2025 Financial Results
Rhea-AI Summary
LevelJump Healthcare (OTC: JMPHF, TSXV: JUMP) reported 2025 revenues of $19.1 million, up from $17.7 million in 2024, a 7.9% year-over-year increase. Canadian Teleradiology Services, the 100%-owned subsidiary, generated $3.84 million EBITDA in 2025.
For 2025, LevelJump recorded EBITDA of $1,662,510 and a net loss from operations of $815,018. Q4 2025 revenues were $5.1 million with EBITDA of $(105,000). According to LevelJump, the Q4 EBITDA decline mainly reflected legal and ancillary costs tied to a shareholder requisition, which the company does not expect to recur. Management highlights record annual revenue and continued organic demand growth. The release also reiterates that EBITDA and adjusted EBITDA are non-IFRS measures used internally to assess operating performance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Revenue up 7.9% YoY to $19.1 million in 2025
- Record annual revenue of $19.1 million in company history
- Subsidiary Canadian Teleradiology Services EBITDA of $3.84 million in 2025
- Full-year 2025 consolidated EBITDA of $1,662,510
- Q4 2025 revenues of $5.1 million support ongoing demand
Negative
- Full-year 2025 net loss from operations of $815,018
- Q4 2025 EBITDA loss of $(105,000)
- Q4 results impacted by legal and ancillary costs from shareholder requisition
Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), is pleased to announce its financial results for the year ended December 31, 2025.
Financial and Operational Highlights
- Revenues were
$19.1 million in 2025 compared to$17.7 million in revenues for 2024, a year over year revenue increase of7.9% .
- Canadian Teleradiology Services, Inc., the Company's
100% owned subsidiary had EBITDA for 2025 of$3.84 million .
2025 Financial Results for fourth quarter and year
Revenues of
$5.1 million in Q4 2025 and$19.1 million for the year 2025 with a net loss from operations of $ for Q4 2025 and a net loss from operations of$815,018 for the year 2025.EBITDA of
$(105,000) for Q4 2025 and$1,662,510 for the year 2025.
Management Comments
"2025 was a strong year, with revenues reaching
Non-IFRS Financial Measures
This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity.
For further details on the results, please refer to LevelJump's Management, Discussion and Analysis and Consolidated Financial Statements for the year ended December 31, 2025, which are available on the Company's website (www.leveljumphealthcare.com) and under the Company's profile on SEDAR+ (www.sedarplus.ca).
About LevelJump Healthcare
LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.
ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.
Mitchell Geisler
Chief Executive Officer
info@leveljumphealthcare.com
647-340-2020
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/305200